Marks, Dalya, Wonderling, David, Thorogood, Margaret, Lambert, Helen, Humphries, Steve E. and Neil, H. A. W.. (2002) Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ, Vol.324 (No.7349). ISSN 0959-535X

Preview

PDF WRAP_thorogood_cost_effecttiveness_bmj.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (277Kb)

Abstract

Objectives To assess the cost effectiveness of strategies to screen for and treat familial hypercholesterolaemia. Design Cost effectiveness analysis. A care pathway for each patient was delineated and the associated probabilities, benefits, and costs were calculated. Participants Simulated population aged 16­54 years in England and Wales. Interventions Identification and treatment of patients with familial hypercholesterolaemia by universal screening, opportunistic screening in primary care, screening of people admitted to hospital with premature myocardial infarction, or tracing family members of affected patients. Main outcome measure Cost effectiveness calculated as cost per life year gained (extension of life expectancy resulting from intervention) including estimated costs of screening and treatment. Results Tracing of family members was the most cost effective strategy (£3097 (&5066, $4479) per life year gained) as 2.6 individuals need to be screened to identify one case at a cost of £133 per case detected. If the genetic mutation was known within the family then the cost per life year gained (£4914) was only slightly increased by genetic confirmation of the diagnosis. Universal population screening was least cost effective (£13 029 per life year gained) as 1365 individuals need to be screened at a cost of £9754 per case detected. For each strategy it was more cost effective to screen younger people and women. Targeted strategies were more expensive per person screened, but the cost per case detected was lower. Population screening of 16 year olds only was as cost effective as family tracing (£2777 with a clinical confirmation). Conclusions Screening family members of people with familial hypercholesterolaemia is the most cost effective option for detecting cases across the whole population.

Item Type:	Journal Article
Subjects:	R Medicine > RA Public aspects of medicine
Divisions:	Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Hypercholesteremia, Medical screening -- Cost effectiveness
Journal or Publication Title:	BMJ
Publisher:	BMJ Group
ISSN:	0959-535X
Date:	1 June 2002
Volume:	Vol.324
Number:	No.7349
Identification Number:	10.1136/bmj.324.7349.1303
Status:	Peer Reviewed
Access rights to Published version:	Restricted or Subscription Access
Funder:	Great Britain. National Health Service (NHS), Merck Sharp & Dohme, British Heart Foundation
Grant number:	95/29/04 (NHS), RG2000025 (BHF), RG93008 (BHF)
References:	1 Goldstein JL, Brown MS. Familial hypercholesterolaemia. In: Scriver CR, Beudet AL, Sly WS,Valle D, eds. The metabolic basis of inherited disease. New York:McGraw Hill, 1995:1215­45. 2 Slack J. Risks of ischaemic heart­disease in familial hyperlipoproteinae­ mic states. Lancet 1969;2:1380­2. 3 Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974;49:476­88. 4 Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000;321:148. 5 Scientific Steering Committee on behalf of the Simon Broome Register Group.Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105­12. 6 Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, et al. Familial hypercholesterolaemia regression study: a randomised trial of low­density­lipoprotein apheresis. Lancet 1995;345:811­6. 7 Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with prava­ statin in patients with coronary heart disease and a broad range of initial cholesterol levels. Lancet 1998;339:1349­57. 8 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383­9. 9 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001­9. 10 Shepherd J, Cobbe M, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hyper­ cholesterolemia. N Engl J Med 1995;333:1301­7. 11 Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholestero­ laemia. BMJ 1991;303:893­6. 12 Humphries SE, Galton D, Nicholls P. Genetic testing for familial hyper­ cholesterolaemia: practical and ethical issues. Q J Med 1997;90:169­81. 13 Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol­ lowering response of the HMG­CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1999;143:41­54. 14 Goldman L, Goldman PA, Williams LW,Weinstein MC. Cost­effectiveness considerations in the treatment of heterozygous familial hypercholeste­ rolemia with medications. Am J Cardiol 1993;72:75­9D. 15 WHO­Human Genetics Programme. Familial hypercholesterolaemia—report of a WHO consulatation. Paris:WHO, 1997. 16 Marks D,Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW. Screening for hypercholesterolaemia versus case finding for famil­ ial hypercholesterolaemia: a systematic review and cost effectiveness analysis. Health Technol Assess 2000;4:1­123. 17 Department of Health. Health survey for England, 1996. London: Station­ ery Office, 1998. 18 Becker DM, Raqueno JV, Yook RM, Kral BG, Blumenthal RS, Moy TF, et al. Nurse­mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease. Arch Intern Med 1998;158:1533­9. 19 Patterson D, Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first degree relatives. Lancet 1972;i:393­9. 20 Williams RR, Hunt SC, Schumacher C, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171­6. 21 Langham S, Thorogood M, Normand C, Muir J, Jones L, Fowler G. Costs and cost effectiveness of health checks conducted by nurses in primary care: the Oxcheck study. BMJ 1996;312:1265­8. 22 Neil HA, Roe L, Godlee RJ, Moore JW, Clark GM, Brown J, et al. Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ 1995;310:569­73. 23 Neil HAW. Problems in measurement: cholesterol. In: Lawrence M, Neil H, Mant D, Fowler G, eds. Prevention of cardiovascular disease: an evidence­based approach.Oxford: Oxford University Press, 1996. 24 Netten A, Dennett J, Knight J. Unit costs of health and social care. Canterbury: Personal Social Serviers Research Unit; University of Kent at Canterbury, 1998. 25 Stevens W, Langham S, Normand C. The cost of CHD in North Thames Region. London: London School of Hygiene and Tropical Medicine, 1999. 26 HM Treasury. Appraisal and evaluation in central government “The Green Book”. London: Stationery Office, 1997. 27 Wilson J, Jungner YG. Principles and practice of mass screening for disease (WHO Public Health Paper 34). Geneva:WHO, 1968. 28 Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of case finding among relatives of patients with known hetero­ zygous familial hypercholesterolaemia. BMJ 2000;321:1497­500. 29 Umans­Eckenhausen MAW, Defesche JC, Sijbrands EJG, Scheerder RLJM, Kastelein JJP. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165­8. 30 Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE,Weinstein MC, et al. Five­hundred life­saving interventions and their cost­effectiveness. Risk Analysis 1995;15:369­90.
URI:	http://wrap.warwick.ac.uk/id/eprint/34566

Request changes to a record

Actions (login required)

View Item